AMRX
Amneal Pharmaceuticals, Inc.
$17.01
-0.01 (-0.06%)
At close · Jul 10
Market Cap
$5.42B
Shares
319,022,792
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Revenue
$3.02B
+8%
FY2025
Net Income
$72.06M
+197.5%
FY2025
Gross Margin
36.88%
+0.4pp
FY2025
Operating Margin
13.05%
+4.1pp
FY2025
Diluted EPS
$0.22
+157.9%
FY2025
Operating Cash Flow
$339.99M
+15.2%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2030 (G) | FY2026 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $1.2B | $3.05B – $3.15B | $3.05B | $3.02B | $2.79B | $2.39B | $2.21B | $2.09B | $1.99B | $1.63B | $1.66B | $0 | |
| — | — | $1.87B | $1.91B | $1.77B | $1.57B | $1.42B | $1.3B | $1.33B | $1.15B | $946.59M | — | |
| — | — | $1.18B | $1.11B | $1.02B | $820.57M | $784.71M | $768.97M | $628.39M | $353M | $716.4M | — | |
| — | — | — | 36.88% | 36.52% | 34.28% | 35.47% | 36.73% | 31.54% | 21.7% | 43.08% | — | |
| — | — | $184.52M | $186.18M | $190.71M | $163.95M | $195.69M | $201.85M | $179.93M | $188.05M | $194.19M | — | |
| — | — | $547.4M | $526.83M | $476.44M | $429.68M | $399.7M | $365.5M | $326.73M | $289.6M | $230.44M | — | |
| — | — | $151.1M | $166.3M | $173.6M | $163.2M | $172.06M | $172.7M | $174.97M | $143.95M | $72.99M | — | |
| — | — | $4.29M | $4.21M | $2.36M | $1.75M | $1.42M | $1.86M | $2.4M | $34.35M | $56.41M | — | |
| — | — | — | — | — | — | — | — | — | — | — | $0 | |
| — | — | $435.52M | $394.1M | $249.33M | $204.37M | -$94.93M | $152.72M | $91.16M | -$248.68M | -$19.67M | — | |
| — | — | — | 13.05% | 8.92% | 8.54% | -4.29% | 7.29% | 4.57% | -15.29% | -1.18% | — | |
| — | — | -$253.62M | -$254.89M | -$304.34M | -$244.64M | -$153.2M | -$121.35M | -$126.94M | $28.44M | -$183.05M | — | |
| — | — | $181.9M | $139.21M | -$55.01M | -$40.27M | -$248.13M | $31.37M | -$35.78M | -$220.24M | -$202.72M | — | |
| — | — | $584K | $11.28M | $18.86M | $8.45M | $6.66M | $11.2M | -$104.36M | $383.33M | -$1.42M | $0 | |
| — | — | $122.12M | $72.06M | -$73.88M | -$79.27M | -$270.58M | $13.16M | $91.06M | -$361.92M | -$19.74M | $0 | |
| — | — | — | 2.39% | -2.64% | -3.31% | -12.23% | 0.63% | 4.57% | -22.25% | -1.19% | — | |
| — | — | $59.2M | $55.88M | $43.01M | $35.27M | -$125.24M | $9.55M | -$22.48M | -$241.66M | -$32.75M | — | |
| — | — | $122.12M | $72.06M | -$116.89M | -$83.99M | -$129.99M | $10.62M | $91.06M | -$361.92M | -$20.92M | — | |
| — | — | $95.71M | $26.84M | -$150.05M | -$127.04M | -$95.11M | $27.34M | $49.86M | -$353.42M | -$23.34M | — | |
| USD/shares | — | — | — | $0.23 | -$0.38 | -$0.48 | -$0.86 | $0.07 | $0.62 | -$0.23 | -$0.07 | — |
| USD/shares | — | — | — | $0.22 | -$0.38 | -$0.48 | -$0.86 | $0.07 | $0.61 | -$0.23 | -$0.07 | — |
| shares | — | — | — | 313.37M | 308.98M | 176.14M | 150.94M | 148.92M | 147.44M | 132.11M | 127.25M | 1000 |
| shares | — | — | — | 324.81M | 308.98M | 176.14M | 150.94M | 151.82M | 148.91M | 132.11M | 127.25M | 1000 |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2018–FY2020: $183M in dividends.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against the industry, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
2.56×
Drug Manufacturers - Specialty & Generic median 2.09×
EV/EBIT
17.89×
Drug Manufacturers - Specialty & Generic median 33.82×
P/E (TTM)
45.88×
Drug Manufacturers - Specialty & Generic median 20.91×
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Segment (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|
| Affordable Medicines Segment | $1,745,524,000 | $1,685,263,000 | $1,471,401,000 | $1,432,073,000 | — | — | — | — |
| AvKARE Segment | $744,728,000 | $662,945,000 | $531,749,000 | $406,110,000 | $349,012,000 | $293,746,000 | — | — |
| Specialty Segment | $528,508,000 | $445,749,000 | $390,457,000 | $374,121,000 | $378,319,000 | $355,567,000 | $317,530,000 | $223,960,000 |
| Amneal Specialty Pharma Segment | — | — | — | $374,121,000 | $378,319,000 | $355,567,000 | $317,530,000 | $223,960,000 |
| Av Kare | — | — | — | — | $349,012,000 | $293,746,000 | $0 | $0 |
| Generics Segment | — | — | $1,471,401,000 | $1,432,073,000 | $1,366,338,000 | $1,343,210,000 | $1,308,843,000 | $1,439,031,000 |
By Geography (USD)
| Component | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|
| United States | $1,602,914,000 | $1,602,997,000 | $946,596,000 |
| Non Us | $20,600,000 | $59,700,000 | $74,536,000 |
By Product & Service (USD)
| Component | 2019-12-31 | 2018-12-31 | 2017-12-31 |
|---|---|---|---|
| Royalties | $2,859,000 | $294,000 | $12,522,000 |
Segment Operating Income
Annual operating income by business segment, as tagged in the company's own XBRL filings. Segments need not sum to the consolidated figure — corporate costs and eliminations are typically unallocated.
By Segment (USD)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|
| Affordable Medicines Segment | $380,798,000 | $270,104,000 | $276,170,000 | $224,156,000 | — | — | — | — |
| Specialty Segment | $116,002,000 | $113,580,000 | $65,298,000 | $72,592,000 | $56,424,000 | — | — | — |
| AvKARE Segment | $83,615,000 | $42,901,000 | $31,512,000 | $3,318,000 | $6,798,000 | -$7,658,000 | — | — |
| Amneal Specialty Pharma Segment | — | — | — | $72,592,000 | $56,424,000 | $56,535,000 | $42,781,000 | $55,560,000 |
| Av Kare | — | — | — | — | $6,798,000 | -$7,658,000 | — | — |
| Generics Segment | — | — | $276,170,000 | $224,156,000 | $281,493,000 | $189,356,000 | -$133,151,000 | $162,901,000 |
Operating Margin by Segment (%)
| Component | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | 2020-12-31 | 2019-12-31 | 2018-12-31 |
|---|---|---|---|---|---|---|---|---|
| Affordable Medicines Segment | 21.8% | 16% | 18.8% | 15.7% | — | — | — | — |
| AvKARE Segment | 11.2% | 6.5% | 5.9% | 0.8% | 1.9% | -2.6% | — | — |
| Specialty Segment | 21.9% | 25.5% | 16.7% | 19.4% | 14.9% | — | — | — |
| Amneal Specialty Pharma Segment | — | — | — | 19.4% | 14.9% | 15.9% | 13.5% | 24.8% |
| Av Kare | — | — | — | — | 1.9% | -2.6% | — | — |
| Generics Segment | — | — | 18.8% | 15.7% | 20.6% | 14.1% | -10.2% | 11.3% |